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Loss-of-function defects in DNA mismatch repair
(MMR), which manifest as high levels of microsatel-
lite instability (MSI), occur in approximately 15% of
all colorectal carcinomas (CRCs). This molecular sub-
set of CRC characterizes patients with better stage-
specific prognoses who experience no benefit from
5-fluorouracil chemotherapy. Most MMR-deficient
(dMMR) CRCs are sporadic, but 15% to 20% are due to
inherited predisposition (Lynch syndrome). High
penetrance of CRCs in germline MMR gene mutation
carriers emphasizes the importance of accurate diag-
nosis of Lynch syndrome carriers. Family-based (Am-
sterdam), patient/family-based (Bethesda), mor-
phology-based, microsatellite-based, and IHC-based
screening criteria do not individually detect all germ-
line mutation carriers. These limitations support the
use of multiple concurrent tests and the screening of all
patients with newly diagnosed CRC. This approach is
resource intensive but would increase detection of in-
herited and de novo germline mutations to guide family
screening. Although CRC prognosis and prediction of
5-fluorouracil response are similar in both the Lynch
and sporadic dMMR subgroups, these subgroups differ
significantly with regard to the implications for family
members. We recommend that new CRCs should be
classified into sporadic MMR-proficient, sporadicdMMR, or Lynch dMMR subgroups. The concurrent use
of MSI testing, MMR protein IHC, and BRAF c.1799T>A
mutation analysis would detect almost all dMMR CRCs,
would classify 94% of all new CRCs into these MMR
subgroups, and would guide secondary molecular test-
ing of the remainder. (J Mol Diagn 2012, 14:91-103; DOI:
10.1016/j.jmoldx.2011.11.001)
Primary colorectal carcinoma (CRC) is a solid tumor that
occurs commonly in US adults. In 2011, the American
Cancer Society expects approximately 142,000 new
cases of CRC. Independent prognostic variables include
stage (extent of disease),1,2 grade (degree of differenti-
ation),1,2 angiolymphatic invasion,3 carcinoembryonic
antigen level,3 and DNA mismatch repair (MMR) sta-
tus.2,4–6 This article focuses on the relevance, molecular
subgroups, and testing strategies for DNA MMR status.
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MSH6) and of MutL homologues (MLH1, PMS2) are sine
qua non components of the human multimeric DNA MMR
protein complexes that correct strand alignment and
base matching errors during DNA replication.7,8 When
any one of these MMR proteins is absent or nonfunc-
tional, the MMR process malfunctions, as reflected by
length alterations in microsatellites, ie, microsatellite in-
stability (MSI).9–11 Therefore, loss-of-function defects in
MMR result in error-prone DNA replication and MSI. The
in vitro effect of this loss is marked—CRC cell lines with
defective MLH1 or MSH2 show a three-log increase in the
rate of dinucleotide repeat length changes per locus per
generation when compared with a MMR-proficient
(pMMR) cell line.12
With the use of panels of microsatellites to screen
CRCs a bimodal distribution of MSI can be observed,
with most cases showing 20% or 60% of microsatel-
lites to be unstable.13 An empirical cutoff at 30% unstable
microsatellites has been adopted, resulting in three test
results: MSI-high (MSI-H; 30% MSI), MSI-low (MSI-L;
0MSI 30%), and microsatellite stability (MSS; MSI 
0%).10 With few exceptions (eg, CRCs due toMSH6 gene
mutations), MSI-L cases arise and behave like MSS
cases and are considered to be pMMR.13,14 MSI-H cases
correlate with differences in stage at presentation and
improved stage-specific prognosis15,16 and are consid-
ered MMR deficient dMMR.13
Approximately 15% of CRCs are dMMR, as estimated
by MSI-H testing.17,18 Most of these (12% to 13%) are
somatically acquired/sporadic,16,19 and the remaining
2% to 3% are due to inherited/germline mutation of one
allele of an MMR gene.20 This latter subgroup character-
izes CRCs diagnosed in the inherited Lynch (also known
as hereditary nonpolyposis colorectal cancer)21–25 and
Muir-Torre26 syndromes.
Both Lynch and sporadic dMMR subgroups differ in
origin but share a final common pathogenesis in terms of
loss of MMR protein function/expression and MSI-H.11,25
Both subgroups have improved stage-specific progno-
ses,2,6,15,16,27–31 and neither group derives benefit from
5-fluorouracil (5-FU) chemotherapy32–36 in contrast to pa-
tients with pMMR CRC. Medical oncologists currently use
MMR status to guide adjuvant 5-FU therapy decisions for
new CRC patients with deep primary tumors without
nodal or distant metastases [American Joint Committee
on Cancer (AJCC) stage II].37 Roughly 40% of new CRC
patients have nodal metastasis without distant metastasis
at presentation (AJCC stage III), and roughly 15% of new
CRC patients have distant metastasis at presentation
(AJCC stage IV).38 Although 5-FU is included in common
combination chemotherapy regimens for patients with
node-positive (stage III) and distant metastatic (stage IV)
CRC, dMMR does not currently preclude use of these
regimens.37 Clinical geneticists use MMR status to
screen for Lynch syndrome and to counsel probands’
unaffected family members.
Understanding the differences in the molecular patho-
genesis for these two dMMR subgroups will facilitate the
use of molecular diagnostic criteria for each subgroup,
allowing logical development of a screening strategy tospecifically assign new cases to a subgroup and then
guiding clinical management, patient surveillance, and
family counseling. Recent emphasis on the detection of
all Lynch probands and subclinical carriers has advo-
cated universal testing for MMR defects in all patients
with newly diagnosed CRC,39 with a goal of improved
clinical decision-making and treatment outcomes. Such
an approach requires a realistic and effective laboratory
practice algorithm for diagnostic testing that will detect all
dMMR cases and then distinguish Lynch and sporadic
dMMR subgroups.
Specific Definition and Pathogenesis of
Sporadic dMMR CRC
Sporadic dMMR CRC comprises 12% to 13% of all new
cases of CRC16,18,19,40–44 and can be broadly defined as
MSI-H sporadic CRC without germline MMR gene dele-
terious mutations.
Most sporadic dMMR CRCs are thought to arise in
sessile serrated adenomas/polyps (SSA/Ps)17,45 in the
proximal colon of older adults.40 SSA/P morphologic
characteristics are recognizably different from those of
conventional adenomatous polyps, which are the precur-
sors for sporadic pMMR and Lynch dMMR CRC.17,45
SSA/Ps with dysplasia are considered the precursor for
sporadic dMMR CRC and show unique molecular fea-
tures, including BRAF c.1799TA mutation, generalized
increase in CpG island methylation (the CpG island
methylator phenotype [CIMP]), MLH1 promoter hyper-
methylation (PHM), and MSI-H.17,45
Like its SSA/P precursor lesion, most invasive sporadic
dMMR CRC exhibits MSI-H and loss of function of the
MLH1 protein due to CpG island hypermethylation in the
MLH1 gene promoter.46–49 More than 95% of sporadic
dMMR CRC is associated withMLH1 PHM.50–52 Reversal
of MLH1 PHM in cell lines with 5=-aza 2=-deoxycytidine
leads to rescue of MLH1 protein expression and MSS,47
implicating MLH1 PHM as etiologic for this sporadic sub-
group of dMMR CRC. MLH1 PHM is rarely detected in
MSS CRC53 or Lynch CRC.53,54 Acquired MLH1 PHM in
Lynch syndrome can be the basis for loss of function of
the remainingMLH1 wild-type allele.49,55,56 Rare cases of
germline MLH1 PHM have been reported.57,58 Therefore,
acquired MLH1 PHM without germ MMR gene mutation
or germline MLH1 PHM appears to be the basis for de-
velopment of sporadic dMMR CRC.
MLH1 PHM in sporadic dMMR CRC is explained in
most cases by the CIMP, a process of DNA hypermeth-
ylation involving multiple gene promoter CpG islands,
includingMLH1.59–63 Using an eight-locus panel to char-
acterize methylation in CRC produces a bimodal distri-
bution of CIMP, with most tumor samples containing ei-
ther 4 (50%) or 6 (75%) methylated loci [CIMP-
high (CIMP-H)].51 The basis for this increased CpG
island methylation may be due to increased DNA meth-
yltransferase activity via mutation or epistatic, transcrip-
tional up-regulation of DNA methyltransferase 3B.64,65
Approximately 70% of CIMP-H CRCs are sporadic dMMR
CRC,51,66,67 and approximately 85% of sporadic dMMR
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have a lower risk for CRC-associated death after adjust-
ing for MSI and BRAF mutation status.68
BRAF gene TA missense mutation at nucleotide 1799
(c.1799TA) is found in 60% of the sporadic dMMR CRC
subgroup and leads to nonsynonymous amino acid sub-
stitution in codon 600 (p.V600E), with constitutive signal-
ing of the BRAF protein.40,41,68–71 A total of 5% to 10% of
pMMR sporadic CRCs68,72 have the BRAF c.1799TA
mutation, but no published cases of Lynch CRC have this
mutation.69,73–76 One case has been found with both
BRAF c.1799TA and a pathogenic germline MMR mu-
tation (Dr. S.N. Thibodeau, personal communication).
This specificity of the BRAF mutation for non-Lynch
CIMP-H CRC comprises a useful testing strategy to iden-
tify and subcategorize dMMR CRC.
The causal pathogenic relationship between CIMP and
BRAF c.1799TA mutation is unclear. Both alterations
may be detected in SSA/Ps,66,77,78 the precursor lesions
of most sporadic dMMR CRC.45 Population-based sam-
ple data show that BRAF c 1799TA mutation status
affects CIMP status,79 suggesting roles for BRAF muta-
tion and mitogen-activated protein kinase pathway acti-
vation in the development of CIMP. However, introduction
of mutant BRAF c.1799TA into CRC cell lines does not
lead to CIMP80; admittedly, established cancer cell lines
do not recapitulate the carcinogenesis process within the
tumor microenvironment. Alternatively, CIMP-mediated
silencing of proapoptotic genes, such as IGFBP7, may
precede and allow survival of clones with the BRAF
c.1799TA mutation.78,80
CIMP, BRAF c.1799TA mutation, MLH1 PHM, and
MSI-H frequently occur together (Figure 1). MSI-H CRCs
are more likely than MSS/MSI-L CRCs to be CIMP-H.18
Conversely, CIMP-H CRCs are more likely than non-
CIMP-H CRCs to be MSI-H, have the BRAF c.1799TA
mutation, and showMLH1 PHM.18,40,81 Most CIMP-H CRCs
contain the BRAF c.1799TA mutant allele, regardless of
MSI status.18,51,68 These data suggest that most sporadic
dMMR CRCs due to MLH1 PHM and resultant MSI-H con-
stitute a large subset within CIMP-H CRC.
One hypothesis is that CIMP-H and BRAF
c.1799TA (p.V600E) lead to MLH1 PHM in some ser-
rated adenomas, with subsequent loss of function of
MLH1, development of MSI-H, and development of
clonal CRC. Stringent molecular diagnostic criteria for
this sporadic dMMR CRC subgroup might be cases
with MSI-H, CIMP-H, MLH1 PHM, MLH1 protein loss,
and BRAF c.1799TA (p.V600E) mutation. The chal-
lenge is to craft a testing algorithm that will identify
almost all patients with dMMR CRC and also distin-
guish the sporadic dMMR CRC subgroup from the
Lynch syndrome subgroup.
Specific Definition and Pathogenesis of
Inherited dMMR CRC (Lynch Syndrome)
Heritable dMMR CRC (Lynch syndrome) comprises ap-
proximately 2.5% of all new cases of CRC24,25,35,82–84and is currently defined as due to a germline MMR genedeleterious mutation.85 Mutations include not only MMR
gene point mutations25 but also large germline deletions
involving MSH2 or MLH1,86–88 germline deletions of the
EPCAM (TACSTD1) gene upstream of MSH2,58 and
germline MLH1 PHM.57,58 Age distribution is unimodal,
with a mode at the age of 45 to 50 years but with a range
of 25 to 70 years.89 Penetrance for CRC is estimated to
be 80% by the age of 80 years90 but may be lower in
female carriers91 and dependent on the underlying mu-
tation.92 These data indicate a benefit for early identifica-
tion and regular surveillance of mutation carriers, contin-
gent on effective intervention, therapy, and treatment.
Estimates and confidence intervals of the proportions
of Lynch CRC cases due to germline mutation of each of
these four MMR genes (weighted proportions: MLH1,
32%;MSH2, 39%;MSH6, 10% to 14%; PMS2, 15%85) are
confounded by incomplete testing of all four MMR genes
in most studies and by skewing in some ethnic groups
with high-frequency founder mutations.93 The remaining
normal second allele might be somatically deleted,94 mu-
tated, or hypermethylated.49,55,56 Biallelic loss of function
of an MMR gene product in Lynch syndrome frequently is
associated with same-locus MMR protein loss and MSI-
H.95 Lynch dMMR CRCs rarely retain MMR protein im-
munoreactivity when a deleterious missense mutation is
present.96 Sensitivity of immunohistochemistry (IHC) for
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Figure 1. The relationship of the CIMP-H, BRAF 1799TA (p.V600E), and
MSI-H variables in new colorectal carcinomas. Each variable is seen in
approximately 15% of new CRC cases, and there is significant overlap among
the variables, detailed in the subjacent table. All cases with MLH1 PHM are
MSI-H, but only 75% to 80% of cases with MSI-H show MLH1 PHM.the presence of a mutation in a given MMR gene is 81%
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a mediocre to substantial interobserver  statistic of 0.49
to 0.79, which varies by expertise of the pathologist,
demonstrating the need for strict scoring criteria to as-
sure quality.97 Sensitivity of MSI-H for germline mutations
in MMR genes is 89% to 92% forMLH1mutations, 90% to
93% for MSH2 mutations, 25% to 76% for MSH6 muta-
tions, and 67% for PMS2 mutations.85,98
The critical relevance of diagnosing patients as having
Lynch syndrome relates to patient follow-up and family
testing. The proband is at increased risk for secondary
carcinomas in the colon and at risk for other Lynch-
associated primary neoplasms.90 For inherited muta-
tions, unaffected siblings from the same parents have a
50% chance of being carriers. Carriers in the family
should be identified for genetic counseling regarding the
fivefold to sixfold increased risk of carcinoma inherent in
Lynch syndrome85,99 and the benefits of enhanced rou-
tine surveillance for Lynch-associated malignant neo-
plasms.99–101 Seven studies reviewed by the Evaluation
of Genomic Applications in Practice and Prevention
Working Group (EGAPP)85 suggest that roughly half of
family members approached avail themselves of coun-
seling opportunities, and 95% of those counseled avail
themselves of recommended MMR gene mutation test-
ing. Most identified carriers (53% to 100%) in these seven
studies agreed to recommended early and follow-up sur-
veillance colonoscopies.85
Final Common Pathogenesis of dMMR CRC
Both inherited (Lynch) and sporadic subgroups of dMMR
CRC share several features. By definition, they lose func-
tion of both allelic gene products for one or more MMR
proteins, and they usually lose immunoreactivity for the
affected MMR protein in paraffin IHC.25,95,96 When either
MLH1 or MSH2 is not expressed, the heterodimer partner
protein (PMS2 for MLH1 and MSH6 for MSH2) is also not
expressed.25 The converse is not true; when either PMS2
or MSH6 is not expressed (without MLH1 or MSH2 gene
alteration), the heterodimer partner proteins (MLH1 for
PMS2 and MSH2 for MSH6) are still expressed,102 pos-
sibly due to alternate heterodimer partners that can sub-
stitute for PMS2 and MSH6. As with MSI-H, improved
stage-specific survival and absence of 5-FU response is
associated with loss of MMR protein expression.30
MSI-H presumably contributes to the pathogenesis of
dMMR CRC via involvement of microsatellites in coding
regions of tumor suppressor or gatekeeper genes, such
as TGFBR2 and BAX.103, 104 MSI-H can be found in the
dysplastic serrated adenoma/polyp precursor of spo-
radic dMMR CRC105 and in the adenomatous polyp pre-
cursor of Lynch dMMR CRC.106 Progression to invasive
CRC may be faster in these dMMR CRC precursors.45
Lynch and sporadic subgroups of dMMR CRC can
show unique morphologic characteristics compared with
pMMR CRC.17 Many MSI-H CRCs show statistically sig-
nificant increases in tumor-infiltrating lymphocytes,
Crohn’s-like reaction, and mucin production and a signif-icant decrease in intraglandular neutrophil-rich (“dirty”)
necrosis.107,108 The tumor-infiltrating lymphocytes may
accumulate in response to neopeptides generated by
frameshift mutations in coding sequences.109,110
Lynch and sporadic subgroups of dMMR CRC also
share different clinical outcomes when compared with
pMMR CRC, including lower stage at initial diagnosis16,68
and improved stage-specific survival.2,6,15,16,27–31 Multi-
variate analyses have found that MSI-H and CIMP-H are
good prognostic variables but that the BRAF c.1799TA
mutation is a poor prognostic variable.68,111,112 Poor
prognosis associated with CIMP-H in previous studies
may have been due to the confounding effects of the
BRAF mutation.68,112–114 MSI-H CRCs are associated
with absence of response to 5-FU therapy,32–36 guiding
current medical oncology management of patients with
AJCC stage II CRC.
Detection of dMMR CRC
Sporadic dMMR CRC
Recognition of the improved prognosis and the absence
of response to 5-FU therapy justify a testing strategy for
the detection of the sporadic dMMR subgroup of CRC.
Assay performance assessment is challenging without a
diagnostic “gold standard” reference method. Given an
expected 142,000 new CRC cases in the United States in
2011, an estimated 17,750 patients (12.5% of the total)
will present with sporadic dMMR CRC.
At the clinical and morphologic level, sporadic dMMR
CRC frequently presents in the proximal aspect of the
colon in older patients, is more common in women, and
shows an expanding growth pattern, mucinous features,
tumor-infiltrating lymphocytes, and absence of intraglan-
dular neutrophil-rich (“dirty”) necrosis.71,115 Sporadic
dMMR CRC can be predicted using the presence of any
three of these factors, with a sensitivity of 98% and spec-
ificity of 48%.71 A similar study found that MSI-H CRC can
be predicted using the presence of any one of seven
factors (old age, proximal site, and five morphologic fac-
tors) with a sensitivity of 92% and specificity of 46%.108
At the IHC and genetic level, MLH1 protein loss was
found in 93 of 97 sporadic dMMR CRC cases (96%), and
MSI-H was found in 96 of these 97 cases (99%).25,116
Importantly, the two methods complemented each other
because all MLH1 PHM cases were identified by one of
the two methods (97 of 97, 100%) (Table 125,49,116–119).
This finding implies that a comprehensive strategy for
detection of sporadic dMMR CRC should use both MSI
and MMR protein IHC testing.
Given sporadic dMMR CRC, the BRAF c.1799TA
mutation is expected in 60% of cases. If this mutation
is present, then Lynch syndrome is virtually exclu-
ded.69,73–76 Therefore, the presence of BRAF c.1799TA
in MSI-H CRC supports a diagnosis of sporadic dMMR
CRC. The absence of this mutation only increases the
likelihood of Lynch syndrome, a diagnosis that still re-
2)
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quencing/deletion testing.
Lynch Syndrome
With the implications of a diagnosis of Lynch syndrome
for at-risk family members, biomarkers have been sought
at the family history, patient history, morphologic, and
molecular levels. None of these approaches detects all
tumors with Lynch syndrome germline abnormalities,
leading to the proposal to screen all patients with newly
diagnosed CRC for heritable mutations.39 With 142,000
new CRC cases expected in the United States in 2011, an
estimated 3550 proband patients (2.5% of the total) will
present with Lynch syndrome CRC. Table 283, 108 sum-
marizes the data on Lynch detection methods.
Table 1. Agreement and Complementarity of IHC Loss and MSI-
No. of
cases Cohort studied
Detection using
IHC loss only, No. (
Probable Sporadic
68 Absence of MLH1 or MSH2
mutations
3 of 9 (MLH1)
46 MSI-H, MLH1 PHM 30 of 36 (MLH1)
257 MLH1 PHM 36 of 36 (MLH1)
Absence of MLH1 or MSH2
mutations
1066 Any MSI, MLH1 PHM 57 of 61
Absence of MLH1 or MSH2
mutations
(MLH1)
1978 Revised Bethesda criteria () 70 of 80
Absence of MLH1 or MSH2
mutations
(MLH1)
Total 196 of 222 (88)
Definite Lynch d
68 MLH1 or MSH2 mutations 5 of 6 (MLH1, MSH2)
257 MLH1 or MSH2 mutations 5 of 5 (MLH1, MSH2)
1066 MLH1, MSH2, MSH6, or PMS2
mutations
21 of 23 (MLH1, MSH
MSH6)
1978 MLH1 or MSH2 mutations 11 of 11 (MLH1, MSH
Total 42 of 45 (93)
dMMR CRC (Ind
3821 Multicenter colon cancer
family registry
667 of 751 (89) (MLH
MSH2, MSH6, PMS
Table 2. Test Performance in Detection of Lynch Syndrome
Test Sensitivity, %
Amsterdam II criteria 42–50
Revised Bethesda criteria 95
Barnetson et al83 95
Greenson et al108 92
MSI 89 (MLH1)
90 (MHS2)
76 (MSH6)
IHC 81 (MLH1)
88 (MHS2)
76 (MSH6)Sequencing 99.5Amsterdam II screening criteria120 are based on family
history of Lynch-associated carcinomas and the identifi-
cation of CRC in one person younger than 50 years.
These criteria have a sensitivity of 42% to 50% and a
specificity of 97% to 98% for the detection of associated
MMR gene mutations.83,121 Thus, use of Amsterdam II
criteria alone would miss the diagnosis of at least 50% of
new Lynch syndrome patients (Table 283,108).
Revised Bethesda criteria122 are based on family his-
tory of Lynch-associated carcinoma, patient age at diag-
nosis, MSI-H histologic findings, and history of other
Lynch-associated carcinomas. One series using these
criteria showed a sensitivity of 95% and a specificity of
38% in the detection of underlying MMR gene muta-
tions.83 Thus, revised Bethesda criteria alone would miss
the diagnosis of 5% of new Lynch syndrome patients
ries of CRCs Stratified by Etiology
Detection using
SI-H only, No. (%)
Detection using both
IHC and MSI, No. (%) Reference
R CRC Subgroup
of 9 9 of 9 (complementary) 117
of 36 (selected for
MSI-H)
36 of 36 49
of 36 36 of 36 25
of 61 61 of 61 116
(complementary)
of 80 80 of 80 118
(complementary)
7 of 186 (95) 186 of 186 (100)
CRC Subgroup
of 6 6 of 6 (complementary) 117
of 5 5 of 5 25
of 23 23 of 23 (complementary) 116
of 11 11 of 11 118
of 45 (91) 45 of 45 (100)
nate Subgroup)
9 of 751 (99.7) 751 of 751 (100)
(complementary)
119
Specificity, %
Estimated Lynch probands missed
(of 3550), No. (%)
97–98 1780–2060 (50–58)
38 180 (5)
14 180 (5)
280 (8)
11–355 (0.3–10)
390–425 (11–12)H in Se
%) M
dMM
8
36
36
60
73
17
MMR
5
5
2, 21
2) 10
41
etermi
1, 7499.9 0 (0)
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because of the common absence of a detailed family
history of cancer in many patients.
Novel models of univariate clinical predictors of MMR
gene mutation status have been combined into a weighted
equation to estimate the probability of an underlying MMR
gene mutation.83 The variables included age, sex, tumor
location, presence of synchronous or metachronous tu-
mors, a first-degree relative with CRC, and a first-degree
relative with endometrial carcinoma. These criteria provided
a sensitivity of 95% with a specificity of 14% for the detec-
tion of underlying MMR gene mutations. This two-step ap-
proach alone would miss the diagnosis of 5% of new Lynch
syndrome cases (Table 283).
A morphology-based study of all MSI-H cases deter-
mined sensitivities of 53% to 70% for individual age, site,
and morphologic features, with a sensitivity of 92% when
any single feature was present.108 These morphologic
criteria alone would miss the diagnosis of 8% of new
Lynch syndrome cases (Table 2108).
Review of data for MSI testing in Lynch syndrome
detection estimated 89% sensitivity for MLH1 mutation
detection, 90% sensitivity for MSH2 mutation detection,
and 76% sensitivity for MSH6 mutation detection.85 Data
from the Colorectal Family Registry indicated that only
0.3% of dMMR CRC showed MMR protein loss without
MSI-H.119 Assuming that most of these data pertained to
Lynch syndrome patients, MSI criteria alone would miss
the diagnosis of 0.3% to 10% new Lynch syndrome pa-
tients (Table 2).83,108
Review of data for IHC testing in Lynch syndrome
detection estimated 81% sensitivity for MLH1 mutation
detection, 88% sensitivity for MSH2 mutation detection,
and 76% sensitivity for MSH6 mutation detection.85 Colo-
rectal Family Registry data found that 11% of dMMR CRC
showed MSI-H without MMR protein loss.119 Assuming
that most of these Colorectal Family Registry data per-
tained to Lynch syndrome patients, IHC criteria alone
would fail to detect 11% to 12% of new Lynch syndrome
patients (Table 2).83,108 Receiver operating characteristic
curves show similar areas under the curves for MSI and
IHC testing.95
High-throughput sequencing-by-synthesis chemical
tests are reducing the cost of targeted resequencing for
known substitutions, insertions, and deletions.123 Se-
quencing of germline DNA to detect germline mutations
in MMR genes is estimated to show a sensitivity of 99.5%
and a specificity of 99.96%.124
Although neither MSI-H nor IHC for MMR proteins has
a sensitivity of 100% for detection of germline MMR gene
mutations, the two assays together are complementary
and would have identified 100% of the 45 Lynch cases in
a set of four CRC series describing a total of 3369 pa-
tients (Table 125,49,116–119).
The incomplete sensitivity of any single testing strategy
emphasizes that these tests should not be used alone or
even as single initial screening tests in a multitest algo-
rithm. Failure to diagnose Lynch syndrome in CRC pa-
tients would preclude recognition and clinical care of
multiple presymptomatic family members who are also atrisk, amplifying the clinical and public health impact of
screening insensitivity.39 Half of the affected first-degree
relatives of patients with Lynch syndrome are expected to
be mutation carriers; thus, the actual number of missed
patient diagnoses (defined as carriers) may be as high as
three to eight times the number of symptomatic pro-
bands.85,116 These are strong arguments in support of
universal testing and detection based on immunopheno-
typic and molecular diagnostic criteria.
Algorithmic Strategies to Detect and Subset
dMMR CRC (Sporadic and Lynch)
Lynch and sporadic dMMR CRC should be diagnosed in
all patients to ensure accurate prognosis, treatment, and
risk assessment for relatives. Clinical presentation, family
history, tumor morphologic features, IHC, and MSI are not
100% sensitive; therefore, a better testing algorithm is
needed to identify dMMR CRC cases and to accurately
assign these cases to Lynch and sporadic subgroups of
dMMR CRC.
Current knowledge allows some rules for creation of a
practical test algorithm. Almost all dMMR CRC will be
detected by the combination of MSI and IHC test-
ing25,49,116–119 (Table 1). In the presence of dMMR, the
additional loss of protein expression of MSH2/MSH6,
MSH6 alone, or PMS2 alone increases the likelihood of
Lynch syndrome. On the other hand, the concomitant
incidence of dMMR, CIMP-H, and MLH1 PHM supports a
diagnosis of sporadic dMMR CRC. Detection of the BRAF
c.1799TA mutation serves to exclude the diagnosis of
Lynch syndrome.
We propose that the MMR screening algorithm include
parallel testing for MSI, BRAF c.1799TA mutation, and
IHC for the four MMR proteins. Figure 1 illustrates the
interrelatedness of these characteristics in a Venn dia-
gram and a table of covariation probabilities. Figure 2
illustrates the proposed algorithm.
Use of this algorithm should allow MMR subgroup as-
signment for most cases (Figure 2). If the CRC is MSS
with normal IHC, then it is pMMR. If the CRC is MSI-H or
MSI-L and IHC shows only MSH6 or PMS2 loss, then the
likelihood of Lynch syndrome increases, and MSH6 or
PMS2 gene sequencing, respectively, is indicated. If the
CRC is MSI-H and IHC shows MSH2 and MSH6 loss, then
the likelihood of Lynch syndrome increases, and MSH2
sequencing/deletion testing is indicated. If the CRC is
MSI-H, IHC shows MLH1 loss, and the BRAF c.1799TA
mutation is present, then it is highly likely sporadic dMMR
CRC. Only with the combination of MSI-H, loss of MLH1
immunoreactivity, and absence of the BRAF mutation is
there substantial uncertainty, and the likelihood of Lynch
syndrome versus sporadic dMMR CRC may vary accord-
ing to the clinical scenario. On the basis of a 5:1 ratio of
sporadic dMMR cases to new Lynch cases and a BRAF
c.1799TA mutation sensitivity of 60% and specificity of
100% for the sporadic dMMR subgroup, Bayes theorem
estimates that 74% of these remaining unassigned cases
will be sporadic dMMR. In this circumstance, CIMP test-
ing, MLH1 PHM testing, and/or MLH1 germline sequenc-
ownstr
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somatic MLH1 PHM would support a diagnosis of spo-
radic dMMR CRC, and presence of an MLH1 germline
mutation, deletion, or hypermethylation would support a
diagnosis of Lynch syndrome.
Alternative Screening Algorithms
National organizations have recommended various test-
ing algorithms to maximize detection of inherited MMR
gene mutations in patients with Lynch syndrome (sum-
marized in Table 3). The National Comprehensive Cancer
Network recommends use of Amsterdam or revised Be-
thesda criteria as the initial screening step.125 This ap-
proach would miss the diagnosis of 5% to 58% of new
Lynch syndrome cases, as well as most sporadic dMMR
CRC cases. EGAPP estimated detection rates and costs
of testing using four different testing strategies: i) MMR
gene sequencing/deletion testing on all probands; ii) MSI
testing, followed by MMR gene sequencing/deletion test-
ing on all MSI-H cases; iii) IHC testing, with protein loss
guiding targeted MMR gene sequencing/deletion testing;
and iv) IHC, with BRAF c.1799TA testing of cases with
MLH1 protein loss.85 Each of these would fail to detect all
dMMR CRC. The first approach could identify most Lynch
cases but not the sporadic dMMR CRC cases. The sec-
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the Centers for Disease Control and Prevention,122 with
similar limitations to the EGAPP model. The (IHC¡se-
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quencing) strategy were more cost-effective for diagno-
sis of Lynch syndrome probands and carriers. However,
11% to 12% of Lynch cases would not be diagnosed due
to the absence of MSI testing to identify MSI-H tumors
with normal IHC in Lynch syndrome patients (Table
125,49,116–119). The American College of Gastroenterol-
ogy recommends initial classification by the revised Be-
thesda criteria, followed by MSI testing and/or IHC.126
This approach would miss 5% of new Lynch cases and
an unknown percentage of sporadic dMMR CRC cases.
Clinical investigations have published algorithms to
detect Lynch syndrome probands84,122,127,128 (summa-
rized in Table 3). Each has been optimized to detect
germline mutations but may also assign cases to the
sporadic dMMR subgroup. The strategy of Lindor et al127
has simultaneous MSI and IHC testing of patients who
also have at least one of the Bethesda criteria. Those
tumors that have MSI-H and/or IHC loss are triaged to
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BRAF c.1799 TA mutation testing. Detection of both
Lynch and sporadic dMMR CRC is facilitated but re-
quires initial clinical stratification, three serial tests with
pathologist evaluations, and summary decisions to as-
sign all cases into molecular subgroups. The strategy of
Vasen et al84 begins with the Bethesda criteria, reflecting
high-risk patients to IHC only and low-risk patients to
either IHC or MSI. IHC loss or MSI-H or MSI-L prompts
resequencing for germline MMR mutations. This ap-
proach would fail to detect sporadic dMMR cases, as
well as 11% of Lynch syndrome cases. The strategy of
Gatalica and Torlakovic128 begins with MSI testing;
MSI-H cases then progress to BRAF c.1799TA mutation
testing, and BRAF mutation-negative tumors proceed to
IHC testing. All Lynch and sporadic dMMR CRC could be
recognized except for the 10% to 14% of Lynch syn-
drome cases that are MSH6 mutant/MSI-L, but four serial
tests with pathologist evaluations/triage decisions would
Table 3. Expected Classification of CRC into dMMR Subgroups
Screening test
Correctly assigned
sporadic dMMR subg
(12.5% in this subgro
Amsterdam II criteria120 only 0.0
Revised Bethesda criteria122 only 0.0
Morphologic analysis only 0.0
MSI testing only 0.0
MMR IHC only 0.0
BRAF c.1799TA test only 0.0
NCCN125 (Amsterdam II or
revised Bethesda criteria
screening first)
Unknown
EGAPP85 model 1 (MMR gene
sequencing/deletion)
0.0
EGAPP model 2 (MSI, then MMR
gene sequencing/deletion if
MSI-H)
0.0
EGAPP model 3 (IHC first, then
MMR gene sequencing if
protein lost)
11.1
EGAPP model 4 (IHC first; then
BRAF if MLH1 lost)
7.5
American College of
Gastroenterology126 (revised
Bethesda criteria screening
first, then MSI or IHC)
Unknown
Lindor et al127 (revised Bethesda
criteria screening, then MSI
and IHC, then MMR gene
sequencing, then BRAF if wild-
type MLH1)
Unknown
Vasen et al84 (revised Bethesda
criteria screening first, then
IHC or MSI)
Unknown
Gatalica and Torlakovic128 (MSI
first, then BRAF, then IHC, then
gene sequencing)
12.5
Concurrent MSI and MMR IHC 0.0
Concurrent MSI, MMR IHC, and
BRAF
7.5
Concurrent MSI, MMR IHC, and
BRAF with follow-up
sequencing as needed
12.5
*Expected percentage of total CRC in each dMMR subgroup.
NCCN, National Comprehensive Cancer Network.be necessary.Universal testing of new CRC patients is predicted to be
relatively cost-effective, particularly when detection of car-
rier status for first- and second-degree relatives of the pro-
band are included.124 Modeling of four molecular testing
strategies estimates that the lowest incremental cost-effec-
tiveness ratio (net cost per life-year saved) would be ob-
tained using a strategy with IHC and BRAFmutation testing,
followed by sequencing of the MMR gene with a loss of
protein expression detected by IHC (MLH1 would be se-
quenced only when BRAF sequence was normal).124 Mod-
eling of both molecular and clinical strategies estimates that
an MSI, IHC, and BRAF mutation testing strategy would be
the most cost-effective.129
Summary of Recommendations
We propose that parallel MSI, MMR protein IHC, and
BRAF c.1799TA mutation testing be performed at the
Correctly assigned to
Lynch dMMR subgroup
(2.5% in this subgroup*)
Correctly assigned to
a dMMR subgroup
(15% in this subgroup*)
1.2 1.2
2.4 2.4
0.0 0.0
0.0 0.0
1.7 1.7
0.0 0.0
1.1–2.4 1.1–2.4
2.5 2.5
2.5 2.5
2.2 13.3
1.7 9.2
2.4 2.4
2.5 2.5
2.5 2.5
2.2 14.7
1.7 1.7
1.7 9.2
2.5 15.0to
roup
up*)time of a new diagnosis of CRC. This would permit as-
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Lynch dMMR subgroups for approximately 94% of CRC
cases, with only the MSI-H, MLH1-lost, and BRAF wild-
type cases (5% to 6% of total CRC) unassigned (Figure 2
and Table 3). This strategy extends the CDC model with
the highest cost-effectiveness of initial IHC with or without
BRAF,124 and also identifies the estimated 11% of pa-
tients with Lynch syndrome who are MSI-H and IHC
immunoreactive.
Our recommended approach would maximize diag-
nostic information using three tests currently available in
most local/regional laboratories and would triage the un-
assigned 6% of the cases to referral laboratories doing
high volumes of hypermethylation, sequencing, and de-
letion testing for resolution of subgroup assignment. An
additional 1.7% of cases (those assigned to the Lynch
syndrome subgroup) would also be referred to define the
germline mutation/deletion involved. Our approach may
be cost-effective, but further study is needed to demon-
strate this. Our expectation is that the cost of testing will
be less than the cost of delayed diagnosis and absent
surveillance of Lynch carriers. At the clinical level, clinical
geneticists will work up and counsel patients with dMMR
CRC, as well as unaffected family members of Lynch
syndrome probands. Medical oncologists will be able to
make prompt therapeutic decisions for their patients with
stage II CRC. Gastroenterologists will be able to define
appropriate follow-up intervals for patients based on
polyp morphologic findings and CRC MMR subgroup.
The end result will be improved diagnostic accuracy re-
garding CRC molecular subgroup assignment, appropri-
ate therapy guided by CRC molecular subgroup, appro-
priate genetic counseling for patients with germline MMR
mutations, and appropriate counseling and screening of
unaffected family members of patients with Lynch syn-
drome for the proband’s known germline MMR mutation.
Acknowledgment
We gratefully acknowledge feedback received on the
original manuscript from Dr. Stephen N. Thibodeau.
References
1. Griffin MR, Bergstralh EJ, Coffey RJ, Beart RW, Jr., Melton LJ, 3rd:
Predictors of survival after curative resection of carcinoma of the
colon and rectum. Cancer 1987, 60:2318–2324
2. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB,
Redston M, Gallinger S: Tumor microsatellite instability and clinical
outcome in young patients with colorectal cancer. N Engl J Med
2000, 342:69–77
3. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP: Ameri-
can Joint Committee on Cancer Prognostic Factors Consensus
Conference: Colorectal Working Group. Cancer 2000, 88:1739–
1757
4. Aarnio M, Mustonen H, Mecklin JP, Jarvinen HJ: Prognosis of colo-
rectal cancer varies in different high-risk conditions. Ann Med 1998,
30:75–80
5. Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP: Better survival rates
in patients with MLH1-associated hereditary colorectal cancer. Gas-
troenterology 1996, 110:682–6876. Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, Pe-
terson BJ, Moon-Tasson L, Mahoney MR, Sargent DJ, O’Connell MJ,Witzig TE, Farr GH, Jr., Goldberg RM, Thibodeau SN: Microsatellite
instability and 8p allelic imbalance in stage B2 and C colorectal
cancers. J Natl Cancer Inst 1999, 91:1295–1303
7. Karran P: Microsatellite instability and DNA mismatch repair in hu-
man cancer. Cancer Biol 1996, 7:15–24
8. Arnheim N, Shibata D: DNA mismatch repair in mammals: role in
disease and meiosis. Curr Opin Genet Dev 1997, 7:364–370
9. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Meck-
lin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR, Petersen GM,
Kinzler KW, Vogelstein B, de la Chapelle A: Clues to the pathogen-
esis of familial colorectal cancer [see comments]. Science 1993,
260:812–816
10. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer
of the proximal colon. Science 1993, 260:816–819
11. Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff
J: Diagnostic microsatellite instability: definition and correlation with
mismatch repair protein expression. Cancer Res 1997, 57:4749–
4756
12. Hanford MG, Rushton BC, Gowen LC, Farber RA: Microsatellite
mutation rates in cancer cell lines deficient or proficient in mismatch
repair. Oncogene 1998, 16:2389–2393
13. Thibodeau SN, French AJ, Cunningham JM, Tester D, Burgart LJ,
Roche PC, McDonnell SK, Schaid DJ, Vockley CW, Michels VV, Farr
GH, Jr., O’Connell MJ: Microsatellite instability in colorectal cancer:
different mutator phenotypes and the principal involvement of
hMLH1. Cancer Res 1998, 58:1713–1718
14. Baudhuin LM, Burgart LJ, Leontovich O, Thibodeau SN: Use of
microsatellite instability and immunohistochemistry testing for the
identification of individuals at risk for Lynch syndrome. Fam Cancer
2005, 4:255–265
15. Myrhoj T, Bisgaard ML, Bernstein I, Svendsen LB, Sondergaard JO,
Bulow S: Hereditary non-polyposis colorectal cancer: clinical fea-
tures and survival. Results from the Danish HNPCC register. Scand
J Gastroenterol 1997, 32:572–576
16. Samowitz WS, Curtin K, Ma KN, Schaffer D, Coleman LW, Leppert
M, Slattery ML: Microsatellite instability in sporadic colon cancer is
associated with an improved prognosis at the population level.
Cancer Epidemiol Biomarkers Prev 2001, 10:917–923
17. Jass JR: Classification of colorectal cancer based on correlation of
clinical, morphological and molecular features. Histopathology
2007, 50:113–130
18. Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer
ES, Hazra A, Hunter DJ, Quackenbush J, Spiegelman D, Giovan-
nucci EL, Fuchs CS, Ogino S: Comprehensive biostatistical analysis
of CpG island methylator phenotype in colorectal cancer using a
large population-based sample. PLoS One 2008, 3:e3698
19. Kim H, Jen J, Vogelstein B, Hamilton SR: Clinical and pathological
characteristics of sporadic colorectal carcinomas with DNA replica-
tion errors in microsatellite sequences. Am J Pathol 1994, 145:148–
156
20. de la Chapelle A: Genetic predisposition to colorectal cancer. Nat
Rev Cancer 2004, 4:769–780
21. Vasen HF, Mecklin JP, Khan PM, Lynch HT: The International Col-
laborative Group on Hereditary Non-Polyposis Colorectal Cancer
(ICG-HNPCC). Dis Colon Rectum 1991, 34:424–425
22. Lynch HT, Smyrk TC, Watson P, Lanspa S, Lynch JF, Lynch PM,
Cavalieri RJ, Boland CR: Genetics, natural history, tumor spectrum,
and pathology of hereditary nonpolyposis colorectal cancer: an
update review. Gastroenterology 1993, 104:1535–1549
23. Rossi SC, Srivastava S: National Cancer Institute workshop on ge-
netic screening for colorectal cancer. J Natl Cancer Inst 1996,
88:331–339
24. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Pelto-
maki P, Chadwick RB, Kaariainen H, Eskelinen M, Jarvinen H, Meck-
lin JP, de LA Chapelle A: Incidence of hereditary nonpolyposis
colorectal cancer and the feasibility of molecular screening for the
disease [see comments]. N Engl J Med 1998, 338:1481–1487
25. Cunningham JM, Kim CY, Christensen ER, Tester DJ, Parc Y, Bur-
gart LJ, Halling KC, McDonnell SK, Schaid DJ, Walsh Vockley C,
Kubly V, Nelson H, Michels VV, Thibodeau SN: The frequency of
hereditary defective mismatch repair in a prospective series of
unselected colorectal carcinomas. Am J Hum Genet 2001, 69:780–
790
100 Funkhouser et al
JMD March 2012, Vol. 14, No. 226. Southey MC, Young MA, Whitty J, Mifsud S, Keilar M, Mead L, Trute
L, Aittomaki K, McLachlan SA, Debinski H, Venter DJ, Armes JE:
Molecular pathologic analysis enhances the diagnosis and manage-
ment of Muir-Torre syndrome and gives insight into its underlying
molecular pathogenesis. Am J Surg Pathol 2001, 25:936–941
27. Watson P, Lin KM, Rodriguez-Bigas MA, Smyrk T, Lemon S,
Shashidharan M, Franklin B, Karr B, Thorson A, Lynch HT: Colorectal
carcinoma survival among hereditary nonpolyposis colorectal car-
cinoma family members. Cancer 1998, 83:259–266
28. Popat S, Hubner R, Houlston RS: Systematic review of microsatellite
instability and colorectal cancer prognosis. J Clin Oncol 2005, 23:
609–618
29. Benatti P, Gafa R, Barana D, Marino M, Scarselli A, Pedroni M,
Maestri I, Guerzoni L, Roncucci L, Menigatti M, Roncari B, Maffei S,
Rossi G, Ponti G, Santini A, Losi L, Di Gregorio C, Oliani C, Ponz de
Leon M, Lanza G: Microsatellite instability and colorectal cancer
prognosis. Clin Cancer Res 2005, 11:8332–8340
30. Lanza G, Gafa R, Santini A, Maestri I, Guerzoni L, Cavazzini L:
Immunohistochemical test for MLH1 and MSH2 expression predicts
clinical outcome in stage II and III colorectal cancer patients. J Clin
Oncol 2006, 24:2359–2367
31. Wright CM, Dent OF, Barker M, Newland RC, Chapuis PH, Bokey EL,
Young JP, Leggett BA, Jass JR, Macdonald GA: Prognostic signif-
icance of extensive microsatellite instability in sporadic clinicopath-
ological stage C colorectal cancer. Br J Surg 2000, 87:1197–1202
32. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Gold-
berg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D,
Redston M, Gallinger S: Tumor microsatellite-instability status as a
predictor of benefit from fluorouracil-based adjuvant chemotherapy
for colon cancer. N Engl J Med 2003, 349:247–257
33. Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero
RT, Cabrera BL, Goel A, Arnold CA, Miyai K, Boland CR: Use of
5-fluorouracil and survival in patients with microsatellite-unstable
colorectal cancer. Gastroenterology 2004, 126:394–401
34. de Vos W, Meulenbeld H, Keibeuker J, Nagengast F, Menko F,
Griffioen G, Cats A, Morreau H, Gelderblom H, Vasen H: Survival
after adjuvant 5-FU treatment for stage III colon cancer in HNPCC
CRC. Int J Cancer 2004, 109:468
35. Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Pinol V,
Xicola RM, Bujanda L, Rene JM, Clofent J, Bessa X, Morillas JD,
Nicolas-Perez D, Paya A, Alenda C: Mismatch repair status in the
prediction of benefit from adjuvant fluorouracil chemotherapy in
colorectal cancer. Gut 2006, 55:848–855
36. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R,
Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C,
Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S:
Defective mismatch repair as a predictive marker for lack of efficacy
of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol
2010, 28:3219–3226
37. Sinicrope FA: DNA mismatch repair and adjuvant chemotherapy in
sporadic colon cancer. Nat Rev Clin Oncol 2010, 7:174–177
38. Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011: the
impact of eliminating socioeconomic and racial disparities on pre-
mature cancer deaths. CA Cancer J Clin 2011, 61:212–236
39. Berg: Recommendations from the EGAPP Working Group: genetic
testing strategies in newly diagnosed individuals with colorectal
cancer aimed at reducing morbidity and mortality from Lynch syn-
drome in relatives. Genet Med 2009, 11:35–41
40. Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Mur-
taugh MA, Wolff RK, Slattery ML: Evaluation of a large, population-
based sample supports a CpG island methylator phenotype in colon
cancer. Gastroenterology 2005, 129:837–845
41. de Vogel S, Weijenberg MP, Herman JG, Wouters KA, de Goeij AF,
van den Brandt PA, de Bruine AP, van Engeland M: MGMT and
MLH1 promoter methylation versus APC. KRAS and BRAF gene
mutations in colorectal cancer: indications for distinct pathways and
sequence of events. Ann Oncol 2009, 20:1216–1222
42. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L,
Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, Chapusot C,
Piard F: Hypermethylator phenotype in sporadic colon cancer: study
on a population-based series of 582 cases. Cancer Res 2008,
68:8541–854643. English DR, Young JP, Simpson JA, Jenkins MA, Southey MC, Walsh
MD, Buchanan DD, Barker MA, Haydon AM, Royce SG, Roberts A,Parry S, Hopper JL, Jass JJ, Giles GG: Ethnicity and risk for
colorectal cancers showing somatic BRAF V600E mutation or CpG
island methylator phenotype. Cancer Epidemiol Biomarkers Prev
2008, 17:1774–1780
44. Campbell PT, Jacobs ET, Ulrich CM, Figueiredo JC, Poynter JN,
McLaughlin JR, Haile RW, Jacobs EJ, Newcomb PA, Potter JD, Le
Marchand L, Green RC, Parfrey P, Younghusband HB, Cotterchio M,
Gallinger S, Jenkins MA, Hopper JL, Baron JA, Thibodeau SN,
Lindor NM, Limburg PJ, Martinez ME: Case-control study of over-
weight, obesity, and colorectal cancer risk, overall and by tumor
microsatellite instability status. J Natl Cancer Inst 102:391–400
45. Snover DC: Update on the serrated pathway to colorectal carci-
noma. Hum Pathol 2011, 42:1–10
46. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H,
Jessup JM, Kolodner R: Methylation of the hMLH1 promoter corre-
lates with lack of expression of hMLH1 in sporadic colon tumors and
mismatch repair-defective human tumor cell lines. Cancer Res 1997,
57:808–811
47. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz
S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD,
Vogelstein B, Kunkel TA, Baylin SB: Incidence and functional con-
sequences of hMLH1 promoter hypermethylation in colorectal car-
cinoma. Proc Natl Acad Sci U S A 1998, 95:6870–6875
48. Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC,
Burgart LJ, Thibodeau SN: Hypermethylation of the hMLH1 promoter
in colon cancer with microsatellite instability. Cancer Res 1998,
58:3455–3460
49. Kuismanen SA, Holmberg MT, Salovaara R, de la Chapelle A, Pel-
tomaki P: Genetic and epigenetic modification of MLH1 accounts for
a major share of microsatellite-unstable colorectal cancers. Am J
Pathol 2000, 156:1773–1779
50. Samowitz WS: The CpG island methylator phenotype in colorectal
cancer. J Mol Diagn 2007, [Epub ahead of press]
51. Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS:
Evaluation of markers for CpG island methylator phenotype (CIMP)
in colorectal cancer by a large population-based sample. J Mol
Diagn 2007, 9:305–314
52. Oliveira C, Westra JL, Arango D, Ollikainen M, Domingo E, Ferreira
A, Velho S, Niessen R, Lagerstedt K, Alhopuro P, Laiho P, Veiga I,
Teixeira MR, Ligtenberg M, Kleibeuker JH, Sijmons RH, Plukker JT,
Imai K, Lage P, Hamelin R, Albuquerque C, Schwartz S, Jr., Lind-
blom A, Peltomaki P, Yamamoto H, Aaltonen LA, Seruca R, Hofstra
RM: Distinct patterns of KRAS mutations in colorectal carcinomas
according to germline mismatch repair defects and hMLH1 methyl-
ation status. Hum Mol Genet 2004, 13:2303–2311
53. Menigatti M, Di Gregorio C, Borghi F, Sala E, Scarselli A, Pedroni M,
Foroni M, Benatti P, Roncucci L, Ponz de Leon M, Percesepe A:
Methylation pattern of different regions of the MLH1 promoter and
silencing of gene expression in hereditary and sporadic colorectal
cancer. Genes Chromosomes Cancer 2001, 31:357–361
54. McGivern A, Wynter CV, Whitehall VL, Kambara T, Spring KJ, Walsh
MD, Barker MA, Arnold S, Simms LA, Leggett BA, Young J, Jass JR:
Promoter hypermethylation frequency and BRAF mutations distin-
guish hereditary non-polyposis colon cancer from sporadic MSI-H
colon cancer. Fam Cancer 2004, 3:101–107
55. Young J, Simms LA, Biden KG, Wynter C, Whitehall V, Karamatic R,
George J, Goldblatt J, Walpole I, Robin SA, Borten MM, Stitz R,
Searle J, McKeone D, Fraser L, Purdie DR, Podger K, Price R,
Buttenshaw R, Walsh MD, Barker M, Leggett BA, Jass JR: Features
of colorectal cancers with high-level microsatellite instability occur-
ring in familial and sporadic settings: parallel pathways of tumori-
genesis. Am J Pathol 2001, 159:2107–2116
56. Rahner N, Friedrichs N, Steinke V, Aretz S, Friedl W, Buettner R,
Mangold E, Propping P, Walldorf C: Coexisting somatic promoter
hypermethylation and pathogenic MLH1 germline mutation in Lynch
syndrome. J Pathol 2008, 214:10–16
57. Morak M, Schackert HK, Rahner N, Betz B, Ebert M, Walldorf C,
Royer-Pokora B, Schulmann K, von Knebel-Doeberitz M, Dietmaier
W, Keller G, Kerker B, Leitner G, Holinski-Feder E: Further evidence
for heritability of an epimutation in one of 12 cases with MLH1
promoter methylation in blood cells clinically displaying HNPCC. Eur
J Hum Genet 2008, 16:804–81158. Niessen RC, Hofstra RM, Westers H, Ligtenberg MJ, Kooi K, Jager
PO, de Groote ML, Dijkhuizen T, Olderode-Berends MJ, Hollema H,
MMR-Defective Colorectal Carcinoma 101
JMD March 2012, Vol. 14, No. 2Kleibeuker JH, Sijmons RH: Germline hypermethylation of MLH1 and
EPCAM deletions are a frequent cause of Lynch syndrome. Genes
Chromosomes Cancer 2009, 48:737–744
59. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe-Toyota M, Baylin SB,
Issa JP: Identification of differentially methylated sequences in colo-
rectal cancer by methylated CpG island amplification. Cancer Res
1999, 59:2307–2312
60. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP:
CpG island methylator phenotype in colorectal cancer. Proc Natl
Acad Sci U S A 1999, 96:8681–8686
61. Sepulveda AR, Jones D, Ogino S, Samowitz W, Gulley ML, Edwards
R, Levenson V, Pratt VM, Yang B, Nafa K, Yan L, Vitazka P: CpG
methylation analysis–current status of clinical assays and potential
applications in molecular diagnostics: a report of the Association for
Molecular Pathology. J Mol Diagn 2009, 11:266–278
62. Teodoridis JM, Hardie C, Brown R: CpG island methylator pheno-
type (CIMP) in cancer: causes and implications. Cancer Lett 2008,
268:177–186
63. Ogino S, Goel A: Molecular classification and correlates in colorectal
cancer. J Mol Diagn 2008, 10:13–27
64. Linhart HG, Lin H, Yamada Y, Moran E, Steine EJ, Gokhale S, Lo G,
Cantu E, Ehrich M, He T, Meissner A, Jaenisch R: Dnmt3b promotes
tumorigenesis in vivo by gene-specific de novo methylation and
transcriptional silencing. Genes Dev 2007, 21:3110–3122
65. Nosho K, Shima K, Irahara N, Kure S, Baba Y, Kirkner GJ, Chen L,
Gokhale S, Hazra A, Spiegelman D, Giovannucci EL, Jaenisch R,
Fuchs CS, Ogino S: DNMT3B expression might contribute to CpG
island methylator phenotype in colorectal cancer. Clin Cancer Res
2009, 15:3663–3671
66. Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh
MD, Barker MA, Arnold S, McGivern A, Matsubara N, Tanaka N,
Higuchi T, Young J, Jass JR, Leggett BA: BRAF mutation is associ-
ated with DNA methylation in serrated polyps and cancers of the
colorectum. Gut 2004, 53:1137–1144
67. Jass JR: Serrated adenoma of the colorectum and the DNA-methy-
lator phenotype. Nat Clin Pract Oncol 2005, 2:398–405
68. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M,
Giovannucci EL, Fuchs CS: CpG island methylator phenotype, mi-
crosatellite instability: BRAF mutation and clinical outcome in colon
cancer. Gut 2009, 58:90–96
69. Domingo E, Laiho P, Ollikainen M, Pinto M, Wang L, French AJ,
Westra J, Frebourg T, Espin E, Armengol M, Hamelin R, Yamamoto
H, Hofstra RM, Seruca R, Lindblom A, Peltomaki P, Thibodeau SN,
Aaltonen LA, Schwartz S, Jr.: BRAF screening as a low-cost effective
strategy for simplifying HNPCC genetic testing. J Med Genet 2004,
41:664–668
70. Koinuma K, Shitoh K, Miyakura Y, Furukawa T, Yamashita Y, Ota J,
Ohki R, Choi YL, Wada T, Konishi F, Nagai H, Mano H: Mutations of
BRAF are associated with extensive hMLH1 promoter methylation in
sporadic colorectal carcinomas. Int J Cancer 2004, 108:237–242
71. Halvarsson B, Anderson H, Domanska K, Lindmark G, Nilbert M:
Clinicopathologic factors identify sporadic mismatch repair-defec-
tive colon cancers. Am J Clin Pathol 2008, 129:238–244
72. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B,
Velculescu VE: Tumorigenesis: rAF/RAS oncogenes and mismatch-
repair status. Nature 2002, 418:934
73. Deng G, Bell I, Crawley S, Gum J, Terdiman JP, Allen BA, Truta B,
Sleisenger MH, Kim YS: BRAF mutation is frequently present in
sporadic colorectal cancer with methylated hMLH1, but not in he-
reditary nonpolyposis colorectal cancer. Clin Cancer Res 2004,
10:191–195
74. Domingo E, Niessen RC, Oliveira C, Alhopuro P, Moutinho C, Espin
E, Armengol M, Sijmons RH, Kleibeuker JH, Seruca R, Aaltonen LA,
Imai K, Yamamoto H, Schwartz S, Jr., Hofstra RM: BRAF-V600E is
not involved in the colorectal tumorigenesis of HNPCC in patients
with functional MLH1 and MSH2 genes. Oncogene 2005, 24:3995–
3998
75. Bessa X, Balleste B, Andreu M, Castells A, Bellosillo B, Balaguer F,
Castellvi-Bel S, Paya A, Jover R, Alenda C, Tito L, Martinez-Villa-
campa M, Vilella A, Xicola RM, Pons E, Llor X: A prospective,
multicenter, population-based study of BRAF mutational analysis for
Lynch syndrome screening. Clin Gastroenterol Hepatol 2008,
6:206–21476. Nakagawa H, Nagasaka T, Cullings HM, Notohara K, Hoshijima N,
Young J, Lynch HT, Tanaka N, Matsubara N: Efficient molecular
screening of Lynch syndrome by specific 3= promoter methylation of
the MLH1 or BRAF mutation in colorectal cancer with high-frequency
microsatellite instability. Oncol Rep 2009, 21:1577–1583
77. O’Brien MJ, Yang S, Mack C, Xu H, Huang CS, Mulcahy E, Amo-
rosino M, Farraye FA: Comparison of microsatellite instability: CpG
island methylation phenotype, BRAF and KRAS status in serrated
polyps and traditional adenomas indicates separate pathways to
distinct colorectal carcinoma end points, Am J Surg Pathol 2006,
30:1491–1501
78. Minoo P, Baker K, Goswami R, Chong G, Foulkes WD, Ruszkiewicz
AR, Barker M, Buchanan D, Young J, Jass JR: Extensive DNA
methylation in normal colorectal mucosa in hyperplastic polyposis.
Gut 2006, 55:1467–1474
79. Tanaka N, Huttenhower C, Nosho K, Baba Y, Shima K, Quacken-
bush J, Haigis KM, Giovannucci E, Fuchs CS, Ogino S: Novel
application of structural equation modeling to correlation structure
analysis of CpG island methylation in colorectal cancer. Am J Pathol
2010, 177:2731–2740
80. Hinoue T, Weisenberger DJ, Pan F, Campan M, Kim M, Young J,
Whitehall VL, Leggett BA, Laird PW: Analysis of the association
between CIMP and BRAF in colorectal cancer by DNA methylation
profiling. PLoS One 2009, 4:e8357
81. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI,
Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D,
Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ,
Thibodeau SN, Jass J, Haile R, Laird PW: CpG island methylator
phenotype underlies sporadic microsatellite instability and is tightly
associated with BRAF mutation in colorectal cancer. Nat Genet
2006, 38:787–793
82. Lynch HT, de la Chapelle A: Hereditary colorectal cancer. N Engl
J Med 2003, 348:919–932
83. Barnetson RA, Tenesa A, Farrington SM, Nicholl ID, Cetnarskyj R,
Porteous ME, Campbell H, Dunlop MG: Identification and survival of
carriers of mutations in DNA mismatch-repair genes in colon cancer.
N Engl J Med 2006, 354:2751–2763
84. Vasen HF, Moslein G, Alonso A, Bernstein I, Bertario L, Blanco I,
Burn J, Capella G, Engel C, Frayling I, Friedl W, Hes FJ, Hodgson S,
Mecklin JP, Moller P, Nagengast F, Parc Y, Renkonen-Sinisalo L,
Sampson JR, Stormorken A, Wijnen J: Guidelines for the clinical
management of Lynch syndrome (hereditary non-polyposis cancer).
J Med Genet 2007, 44:353–362
85. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN:
EGAPP supplementary evidence review: dNA testing strategies
aimed at reducing morbidity and mortality from Lynch syndrome.
Genet Med 2009, 11:42–65
86. Wijnen J, van der Klift H, Vasen H, Khan PM, Menko F, Tops C,
Meijers Heijboer H, Lindhout D, Moller P, Fodde R: MSH2 genomic
deletions are a frequent cause of HNPCC. Nat Genet 1998, 20:326–
328
87. Taylor CF, Charlton RS, Burn J, Sheridan E, Taylor GR: Genomic
deletions in MSH2 or MLH1 are a frequent cause of hereditary
non-polyposis colorectal cancer: identification of novel and recur-
rent deletions by MLPA. Hum Mutat 2003, 22:428–433
88. Kastrinos F, Stoffel EM, Balmana J, Steyerberg EW, Mercado R,
Syngal S: Phenotype comparison of MLH1 and MSH2 mutation
carriers in a cohort of 1,914 individuals undergoing clinical genetic
testing in the United States. Cancer Epidemiol Biomarkers Prev
2008, 17:2044–2051
89. de Jong AE, Nagengast FM, Kleibeuker JH, van de Meeberg PC,
van Wijk HJ, Cats A, Griffioen G, Vasen HF: What is the appropriate
screening protocol in Lynch syndrome? Fam Cancer 2006, 5:373–
378
90. Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ:
Life-time risk of different cancers in hereditary non-polyposis colo-
rectal cancer (HNPCC) syndrome. Int J Cancer 1995, 64:430–433
91. Barrow E, Alduaij W, Robinson L, Shenton A, Clancy T, Lalloo F, Hill
J, Evans DG: Colorectal cancer in HNPCC: cumulative lifetime inci-
dence, survival and tumour distribution: A report of 121 families with
proven mutations. Clin Genet 2008, 74:233–242
92. Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy
M, Guimbaud R, Buecher B, Bignon YJ, Caron O, Colas C, Nogues
C, Lejeune-Dumoulin S, Olivier-Faivre L, Polycarpe-Osaer F, Nguyen
102 Funkhouser et al
JMD March 2012, Vol. 14, No. 2TD, Desseigne F, Saurin JC, Berthet P, Leroux D, Duffour J,
Manouvrier S, Frebourg T, Sobol H, Lasset C, Bonaiti-Pellie C:
Cancer risks associated with germline mutations in MLH1. MSH2,
and MSH6 genes in Lynch syndrome. JAMA 2011, 305:2304–2310
93. Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen
M, Harkonen N, Julkunen R, Kangas E, Ojala S, Tulikoura J, Valkamo
E, Jarvinen H, Mecklin JP, Aaltonen LA, de LA Chapelle A: Popula-
tion-based molecular detection of hereditary nonpolyposis colorec-
tal cancer. J Clin Oncol 2000, 18:2193–2200
94. Tuupanen S, Karhu A, Jarvinen H, Mecklin JP, Launonen V, Aaltonen
LA: No evidence for dual role of loss of heterozygosity in hereditary
non-polyposis colorectal cancer. Oncogene 2007, 26:2513–2517
95. Engel C, Forberg J, Holinski-Feder E, Pagenstecher C, Plaschke J,
Kloor M, Poremba C, Pox CP, Ruschoff J, Keller G, Dietmaier W,
Rummele P, Friedrichs N, Mangold E, Buettner R, Schackert HK,
Kienle P, Stemmler S, Moeslein G, Loeffler M: Novel strategy for
optimal sequential application of clinical criteria, immunohistochem-
istry and microsatellite analysis in the diagnosis of hereditary non-
polyposis colorectal cancer. Int J Cancer 2006, 118:115–122
96. Ollila S, Dermadi Bebek D, Jiricny J, Nystrom M: Mechanisms of
pathogenicity in human MSH2 missense mutants. Hum Mutat 2008,
29:1355–1363
97. Overbeek LI, Ligtenberg MJ, Willems RW, Hermens RP, Blokx WA,
Dubois SV, van der Linden H, Meijer JW, Mlynek-Kersjes ML,
Hoogerbrugge N, Hebeda KM, van Krieken JH: Interpretation of
immunohistochemistry for mismatch repair proteins is only reliable in
a specialized setting. Am J Surg Pathol 2008, 32:1246–1251
98. Shia J: Immunohistochemistry versus microsatellite instability testing
for screening colorectal cancer patients at risk for hereditary non-
polyposis colorectal cancer syndrome, part I: The utility of immuno-
histochemistry. J Mol Diagn 2008, 10:293–300
99. Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, Peltomaki P,
Aaltonen LA, Mecklin JP: Ten years after mutation testing for Lynch
syndrome: cancer incidence and outcome in mutation-positive and
mutation-negative family members. J Clin Oncol 2009, 27:4793–
4797
100. Vasen HF, van Ballegooijen M, Buskens E, Kleibeuker JK, Taal BG,
Griffioen G, Nagengast FM, Menko FH, Meera Khan P: A cost-
effectiveness analysis of colorectal screening of hereditary nonpol-
yposis colorectal carcinoma gene carriers. Cancer 1998, 82:1632–
1637
101. Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA,
Peltomaki P, De LA Chapelle A, Mecklin JP: Controlled 15-year trial
on screening for colorectal cancer in families with hereditary non-
polyposis colorectal cancer. Gastroenterology 2000, 118:829–834
102. Shia J, Tang LH, Vakiani E, Guillem JG, Stadler ZK, Soslow RA,
Katabi N, Weiser MR, Paty PB, Temple LK, Nash GM, Wong WD,
Offit K, Klimstra DS: Immunohistochemistry as first-line screening for
detecting colorectal cancer patients at risk for hereditary nonpol-
yposis colorectal cancer syndrome: a 2-antibody panel may be as
predictive as a 4-antibody panel. Am J Surg Pathol 2009, 33:1639–
1645
103. Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L,
Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ,
Bertagnolli MM, Boland CR: Characterization of sporadic colon can-
cer by patterns of genomic instability. Cancer Res 2003, 63:1608–
1614
104. Woerner SM, Benner A, Sutter C, Schiller M, Yuan YP, Keller G, Bork
P, Doeberitz MK, Gebert JF: Pathogenesis of DNA repair-deficient
cancers: a statistical meta-analysis of putative Real Common Target
genes. Oncogene 2003, 22:2226–2235
105. Iino H, Jass JR, Simms LA, Young J, Leggett B, Ajioka Y, Watanabe
H: DNA microsatellite instability in hyperplastic polyps, serrated
adenomas, and mixed polyps: a mild mutator pathway for colorectal
cancer?. J Clin Pathol 1999, 52:5–9
106. Iino H, Simms L, Young J, Arnold J, Winship IM, Webb SI, Furlong
KL, Leggett B, Jass JR: DNA microsatellite instability and mismatch
repair protein loss in adenomas presenting in hereditary non-polyp-
osis colorectal cancer. Gut 2000, 47:37–42
107. Gologan A, Krasinskas A, Hunt J, Thull DL, Farkas L, Sepulveda AR:
Performance of the revised Bethesda guidelines for identification of
colorectal carcinomas with a high level of microsatellite instability.
Arch Pathol Lab Med 2005, 129:1390–1397108. Greenson JK, Huang SC, Herron C, Moreno V, Bonner JD, Tomsho
LP, Ben-Izhak O, Cohen HI, Trougouboff P, Bejhar J, Sova Y,
Pinchev M, Rennert G, Gruber SB: Pathologic predictors of micro-
satellite instability in colorectal cancer. Am J Surg Pathol 2009,
33:126–133
109. Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P,
Knaebel HP, Tariverdian M, Benner A, von Knebel Doeberitz M:
Immune response against frameshift-induced neopeptides in HN-
PCC patients and healthy HNPCC mutation carriers. Gastroenterol-
ogy 2008, 134:988–997
110. Speetjens FM, Kuppen PJ, Morreau H, van der Burg SH: Immune
response against frameshift-induced neopeptides in HNPCC pa-
tients and healthy HNPCCmutation carriers. Gastroenterology 2008,
135:711–712; author reply 712–713
111. Lee S, Cho NY, Choi M, Yoo EJ, Kim JH, Kang GH: Clinicopatho-
logical features of CpG island methylator phenotype-positive colo-
rectal cancer and its adverse prognosis in relation to KRAS/BRAF
mutation. Pathol Int 2008, 58:104–113
112. Kim JH, Shin SH, Kwon HJ, Cho NY, Kang GH: Prognostic implica-
tions of CpG island hypermethylator phenotype in colorectal can-
cers. Virchows Arch 2009, 455:485–494
113. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Mur-
taugh MA, Wolff RK, Slattery ML: Poor survival associated with the
BRAF V600E mutation in microsatellite-stable colon cancers. Can-
cer Res 2005, 65:6063–6069
114. Dahlin AM, Palmqvist R, Henriksson ML, Jacobsson M, Eklof V,
Rutegard J, Oberg A, Van Guelpen BR: The role of the CpG island
methylator phenotype in colorectal cancer prognosis depends on
microsatellite instability screening status. Clin Cancer Res 2010,
16:1845–1855
115. Jenkins MA, Hayashi S, O’Shea AM, Burgart LJ, Smyrk TC, Shimizu
D, Waring PM, Ruszkiewicz AR, Pollett AF, Redston M, Barker MA,
Baron JA, Casey GR, Dowty JG, Giles GG, Limburg P, Newcomb P,
Young JP, Walsh MD, Thibodeau SN, Lindor NM, Lemarchand L,
Gallinger S, Haile RW, Potter JD, Hopper JL, Jass JR: Pathology
features in Bethesda guidelines predict colorectal cancer microsat-
ellite instability: a population-based study. Gastroenterology 2007,
133:48–56
116. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P,
Nakagawa H, Sotamaa K, Prior TW, Westman J, Panescu J, Fix D,
Lockman J, Comeras I, de la Chapelle A: Screening for the Lynch
syndrome (hereditary nonpolyposis colorectal cancer). N Engl
J Med 2005, 352:1851–1860
117. Debniak T, Kurzawski G, Gorski B, Kladny J, Domagala W, Lubinski
J: Value of pedigree/clinical data, immunohistochemistry and mic-
rosatellite instability analyses in reducing the cost of determining
hMLH1 and hMSH2 gene mutations in patients with colorectal can-
cer. Eur J Cancer 2000, 36:49–54
118. Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X,
Xicola RM, Rodriguez-Moranta F, Paya A, Jover R, Bessa X: Accu-
racy of revised Bethesda guidelines, microsatellite instability, and
immunohistochemistry for the identification of patients with heredi-
tary nonpolyposis colorectal cancer. JAMA 2005, 293:1986–1994
119. Cicek M, Lindor N, Gallinger S, Bapat B, Hopper J, Jenkins M,
Young J, Buchanan D, Walsh M, Le Marchand L, Burnett T, New-
comb P, Grady W, Haile R, Casey G, Plummer S, Krumroy L, Baron
J, Thibodeau S: Quality assessment and correlation of MSI and IHC
markers among population- and clinic-based colorectal tumors. J
Mol Diagn 2011, 13:271–281
120. Vasen HF, Watson P, Mecklin JP, Lynch HT: New clinical criteria for
hereditary nonpolyposis colorectal cancer (HNPCC. Lynch syn-
drome) proposed by the International Collaborative Group on HN-
PCC. Gastroenterology 1999, 116:1453–1456
121. Southey MC, Jenkins MA, Mead L, Whitty J, Trivett M, Tesoriero AA,
Smith LD, Jennings K, Grubb G, Royce SG, Walsh MD, Barker MA,
Young JP, Jass JR, St John DJ, Macrae FA, Giles GG, Hopper JL:
Use of molecular tumor characteristics to prioritize mismatch repair
gene testing in early-onset colorectal cancer. J Clin Oncol 2005,
23:6524–6532
122. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A,
Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton
SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey
SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freed-
man AN, Srivastava S: Revised Bethesda Guidelines for hereditary
MMR-Defective Colorectal Carcinoma 103
JMD March 2012, Vol. 14, No. 2nonpolyposis colorectal cancer (Lynch syndrome) and micro-
satellite instability. J Natl Cancer Inst 2004, 96:261–268
123. Bansal V, Tewhey R, Leproust EM, Schork NJ: Efficient and cost
effective population resequencing by pooling and in-solution hybrid-
ization. PLoS One 2011, 6:e18353
124. MvunduraM,Grosse SD, Hampel H, Palomaki GE: The cost-effectiveness
of genetic testing strategies for Lynch syndrome among newly diagnosed
patients with colorectal cancer. Genet Med 2010, 12:93–104
125. National Comprehensive Cancer Network: NCCN Clinical Practice
Guidelines in Oncology: Colorectal Cancer Screening. Version
2.2011. Rockledge, PA: National Comprehensive Cancer Network,
2010:LS-1. Available online with free registration: http://www.
nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf.
Accessed September 17, 2011126. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA,
Inadomi JM: American College of Gastroenterology guidelines for
colorectal cancer screening 2009 [corrected]. Am J Gastroenterol
2009, 104:739–750
127. Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu
KH, Lynch P, Burke W, Press N: Recommendations for the care of
individuals with an inherited predisposition to Lynch syndrome: a
systematic review. JAMA 2006, 296:1507–1517
128. Gatalica Z, Torlakovic E: Pathology of the hereditary colorectal
carcinoma. Fam Cancer 2008, 7:15–26
129. Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M,
Boland CR, Ford J, Elkin E, Phillips KA: Strategies to identify the
Lynch syndrome among patients with colorectal cancer: a cost-
effectiveness analysis. Ann Intern Med 2011, 155:69–79
